​
​

Esperion Therapeutics (ESPR) Revenue & Revenue Breakdown

OverviewForecastOwnershipFinancialsChartTranscripts

Esperion Therapeutics Revenue Highlights

Latest Revenue (Y)

$116.33M

Latest Revenue (Q)

$51.63M

Main Segment (Y)

Product

Esperion Therapeutics Revenue by Period

Esperion Therapeutics Revenue by Year

DateRevenueChange
2023-12-31-54.14%
2022-12-31--3.79%
2021-12-31--65.52%
2020-12-31-53.37%
2019-12-31--19.57%
2018-12-31-100.00%
2017-12-31-100.00%
2016-12-31-100.00%
2015-12-31-100.00%
2014-12-31--100.00%
2013-12-31-100.00%
2012-12-31-100.00%
2011-12-31-100.00%
2002-12-31-100.00%
2001-12-31--100.00%
2000-12-31-100.00%
1999-12-31--

Esperion Therapeutics generated $116.33M in revenue during NA 2023, up 54.14% compared to the previous quarter, and up 63.06% compared to the same period a year ago.

Esperion Therapeutics Revenue by Quarter

DateRevenueChange
2024-09-30--30.07%
2024-06-30--46.39%
2024-03-31-327.09%
2023-12-31--5.06%
2023-09-30-31.73%
2023-06-30-5.99%
2023-03-31-29.29%
2022-12-31--0.85%
2022-09-30-0.74%
2022-06-30-0.03%
2022-03-31-22.30%
2021-12-31-6.88%
2021-09-30--64.56%
2021-06-30-409.64%
2021-03-31--17.22%
2020-12-31-151.45%
2020-09-30--98.19%
2020-06-30-11434.57%
2020-03-31-87.37%
2019-12-31-0.10%
2019-09-30--0.10%
2019-06-30--99.32%
2019-03-31--21.17%
2018-12-31-100.00%
2018-09-30-100.00%
2018-06-30-100.00%
2018-03-31-100.00%
2017-12-31-100.00%
2017-09-30-100.00%
2017-06-30-100.00%
2017-03-31-100.00%
2016-12-31-100.00%
2016-09-30-100.00%
2016-06-30-100.00%
2016-03-31-100.00%
2015-12-31-100.00%
2015-09-30-100.00%
2015-06-30-100.00%
2015-03-31-100.00%
2014-12-31-100.00%
2014-09-30-100.00%
2014-06-30-100.00%
2014-03-31-100.00%
2013-12-31-100.00%
2013-09-30-100.00%
2013-06-30-100.00%
2013-03-31-100.00%
2012-12-31-100.00%
2012-09-30-100.00%
2012-06-30-100.00%
2012-03-31-100.00%
2003-09-30-100.00%
2003-06-30-100.00%
2003-03-31-100.00%
2002-12-31-100.00%
2002-09-30-100.00%
2002-06-30-100.00%
2002-03-31-100.00%
2001-12-31-100.00%
2001-09-30--100.00%
2001-06-30--
2001-03-31--
2000-12-31--
2000-09-30--
2000-06-30-100.00%
2000-03-31--

Esperion Therapeutics generated $51.63M in revenue during Q3 2024, up -30.07% compared to the previous quarter, and up 200.23% compared to the same period a year ago.

Esperion Therapeutics Revenue Breakdown

Esperion Therapeutics Revenue Breakdown by Product

Annual Revenue by Product

Product/ServiceDec 23Dec 22Dec 21Dec 20Dec 19
Product-----
Collaboration Revenue-----
Royalty Revenue From DSE-----
Ongoing Regulatory And Development Activities Revenue-----
Product Sales Bulk Tablets And Royalty Revenue Of Nilemdo And Nustendi-----
Milestone Marketing Authorization Approval Nustendi-----
License For Intellectual Property Revenue-----

Esperion Therapeutics's latest annual revenue breakdown by segment (product or service), as of Dec 23: Product (67.34%), and Collaboration Revenue (32.66%).

Quarterly Revenue by Product

Product/ServiceSep 24Mar 24Dec 23Sep 23Jun 23Mar 23Dec 22Sep 22Jun 22Mar 22Dec 21Sep 21Jun 21Mar 21Dec 20Sep 20Jun 20Mar 20Dec 19Sep 19
Product--------------------
Collaboration Revenue--------------------
Royalty Revenue And Product Sales Bulk Tablets--------------------
Royalty Revenue And Product Sales Bulk Tablets Nilemdo And Nustendi--------------------
Product Sales Bulk Tablets Nilemdo And Nustendi--------------------
Milestone Marketing Authorization Approval Nustendi--------------------
Regulatory Performance Obligations--------------------
Ongoing Regulatory Activities Revenue--------------------
License For Intellectual Property Revenue--------------------
Ongoing Regulatory And Development Activities Revenue--------------------

Esperion Therapeutics's latest quarterly revenue breakdown by segment (product or service), as of Sep 24: Product (60.25%), and Collaboration Revenue (39.75%).

Esperion Therapeutics Peer Comparison by Revenue

TickerCompanyLast Year RevenueLast Quarter Revenue
ELANElanco Animal Health--
CTLTCatalent--
NBIXNeurocrine Biosciences--
ALKSAlkermes--
PBHPrestige Consumer Healthcare--
PAHCPhibro Animal Health--
PCRXPacira BioSciences--
COLLCollegium Pharmaceutical--
ANIPANI Pharmaceuticals--
ITCIIntra-Cellular Therapies--
IRWDIronwood Pharmaceuticals--
EGRXEagle Pharmaceuticals--
DCPHDeciphera Pharmaceuticals--
KMDAKamada--
SIGASIGA--
LFCRLifecore Biomedical--
ESPREsperion Therapeutics--
RMTIRockwell Medical--
AVDLAvadel Pharmaceuticals--
AGRXAgile Therapeutics--

ESPR Revenue FAQ

What is Esperion Therapeutics’s yearly revenue?

Esperion Therapeutics's yearly revenue for 2023 was $116.33M, representing an increase of 54.14% compared to 2022. The company's yearly revenue for 2022 was $75.48M, representing a decrease of -3.79% compared to 2021. ESPR's yearly revenue for 2021 was $78.45M, representing a decrease of -65.52% compared to 2020.

What is Esperion Therapeutics’s quarterly revenue?

Esperion Therapeutics's quarterly revenue for Q3 2024 was $51.63M, a -30.07% decrease from the previous quarter (Q2 2024), and a 52.00% increase year-over-year (Q3 2023). The company's quarterly revenue for Q2 2024 was $73.83M, a -46.39% decrease from the previous quarter (Q1 2024), and a 186.33% increase year-over-year (Q2 2023). ESPR's quarterly revenue for Q1 2024 was $137.74M, a 327.09% increase from the previous quarter (Q4 2023), and a 466.14% increase year-over-year (Q1 2023).

What is Esperion Therapeutics’s revenue growth rate?

Esperion Therapeutics's revenue growth rate for the last 3 years (2021-2023) was 48.30%, and for the last 5 years (2019-2023) was -21.59%.

What are Esperion Therapeutics’s revenue streams?

Esperion Therapeutics's revenue streams in c 23 are Product, and Collaboration Revenue. Product generated $78.34M in revenue, accounting 67.34% of the company's total revenue, up 40.23% year-over-year. Collaboration Revenue generated $38M in revenue, accounting 32.66% of the company's total revenue, up 93.75% year-over-year.

What is Esperion Therapeutics’s main source of revenue?

For the fiscal year ending Dec 23, the largest source of revenue of Esperion Therapeutics was Product. This segment made a revenue of $78.34M, representing 67.34% of the company's total revenue.